Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Paydas, S.
Right arrow Articles by Burgut, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paydas, S.
Right arrow Articles by Burgut, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1045-1050, 2003
© 2003 European Society for Medical Oncology

Original Paper

Survivin and aven: two distinct antiapoptotic signals in acute leukemias

S. Paydas1,+, K. Tanriverdi2, S. Yavuz1, U. Disel1, B. Sahin1 and R. Burgut3

Departments of 1 Oncology, 2 Hematology and 3 Biostatistics, Cukurova University Faculty of Medicine, Adana, Turkey

Received 11 January 2003; revised 3 March 2003; accepted 4 March 2003

Background:

Antiapoptotic signals are important in the development, progression and prognosis of malignant tumors. The aim of this study was to determine the two distinct antiapoptotic signals—survivin and aven—in acute leukemias and compare them with clinical and hematological findings and response to therapy. Real-time quantitative PCR was used and survivin and aven were detected at the messenger (m)RNA level.

Patients and methods:

Sixty-five patients with acute leukemia [37 with acute myeloblastic leukemia (AML) and 28 with acute lymphoblastic leukemia (ALL)] were used as the study group and 10 healthy subjects were used as the control group.

Results:

Survivin was between 0.0 and 0.829 copy number/cell (median 0.0721, mean 0.5424301909 ± 0.139799488589) and aven was between 0.0 and 0.853 copy number/cell (median 0.0124, mean 0.070335542 ± 0.1524685709). We found an important association between survivin and aven (P = 0.000). Both survivin and aven were higher in the study group than in the controls (P = 0.001 and 0.035, respectively). When we compared survivin and aven with other clinical and hematological parameters, there was an important association between survivin and extramedullary involvement (P = 0.033), survivin and alkaline phosphatase (P = 0.06), white blood cell (WBC) count and lactate dehydrogenase (LDH) (P = 0.000), WBC count and uric acid (P = 0.074), hemoglobin level and LDH (P = 0.072), LDH and uric acid (P = 0.057), CD7 expression and survivin (P = 0.097), and CD34 expression and aven (P = 0.058). Response to therapy was evaluated according to the survivin and aven levels. Survivin level was lower in refractory patients as compared with complete responders (P = 0.085). Aven level was higher in patients with relapse as compared with non-relapse patients (P = 0.04). There was no important association between survivin or aven and performance status, lymphadenopathy or organomegaly.

Conclusions:

Both survivin and aven are important antiapoptotic signals in acute leukemias, and the association between extramedullary involvement, CD7 expression and CD34 expression, which are important poor prognostic indicators in acute leukemias, suggests that survivin and/or aven may be novel prognostic indicators in acute leukemias. Further studies with a higher number of patients will be more informative.

Key words: acute leukemia, antiapoptotic signals, aven, CD7 expression, CD34 expression, extramedullary involvement, response to therapy, survivin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 haematolHome page
A. Troeger, M. Siepermann, G. Escherich, R. Meisel, R. Willers, S. Gudowius, T. Moritz, H.-J. Laws, H. Hanenberg, U. Goebel, et al.
Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia
Haematologica, August 1, 2007; 92(8): 1043 - 1050.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Grube, S. Moritz, E. C. Obermann, K. Rezvani, A. Mackensen, R. Andreesen, and E. Holler
CD8+ T cells Reactive to Survivin Antigen in Patients with Multiple Myeloma
Clin. Cancer Res., February 1, 2007; 13(3): 1053 - 1060.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
B. Gyurkocza, J. Plescia, C. M. Raskett, D. S. Garlick, P. A. Lowry, B. Z. Carter, M. Andreeff, M. Meli, G. Colombo, and D. C. Altieri
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
J Natl Cancer Inst, August 2, 2006; 98(15): 1068 - 1077.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. J. Liu, R. W. Huang, D. J. Lin, J. Peng, X. Y. Wu, Q. Lin, X. L. Pan, Y. Q. Song, M. H. Zhang, M. Hou, et al.
Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-{gamma} ligands induces apoptosis on human myeloid leukemia cells in vitro
Ann. Onc., March 1, 2005; 16(3): 455 - 459.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.